Education
About Us
Working with TipRanks
Follow Us
Alpha Teknova, Inc. (TKNO)
:TKNO
TKNO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.16 - $10.37
Previous CloseN/A
Volume51.57K
Average Volume (3M)480.36K
Market Cap
$346.80M
Enterprise Value$445.46M
Total Cash (Recent Filing)$3.71M
Total Debt (Recent Filing)$30.17M
Price to Earnings (P/E)―
Beta0.91
Next Earnings
May 07, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.58
Shares Outstanding53,436,806
10 Day Avg. Volume351,525
30 Day Avg. Volume480,358
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)8.30
Price to Cash Flow (P/CF)-83.60
P/FCF Ratio0.00
Enterprise Value/Market Cap1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit61.60
Enterprise Value/Ebitda-20.97
Forecast
1Y Price Target
$10.00Price Target Upside50.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
Alpha Teknova News
PremiumCompany Announcements
Alpha Teknova’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Alpha Teknova Reports Steady Revenue Growth in 2024
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceQ4 revenues of $9.3M beat the Street's $8.8M, showing stronger than expected performance.
ProfitabilityTeknova's path to profitability should boost investor confidence given the high level of visibility.
Bears Say
Macro EnvironmentThe company called out cautiousness from customers related to the funding environment and other macro uncertainties.
Revenue Guidance2025 revenue guidance of $39-42M is below consensus estimates, leading to modest expected top line growth.
---
Ownership Overview
50.68% Insiders
1.61% Mutual Funds
2.26% Other Institutional Investors
44.10% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
TKNO FAQ
What was Alpha Teknova, Inc.’s price range in the past 12 months?
Alpha Teknova, Inc. lowest stock price was $1.16 and its highest was $10.37 in the past 12 months.
What is Alpha Teknova, Inc.’s market cap?
Alpha Teknova, Inc.’s market cap is $346.80M.
When is Alpha Teknova, Inc.’s upcoming earnings report date?
Alpha Teknova, Inc.’s upcoming earnings report date is May 07, 2025 which is in 11 days.
How were Alpha Teknova, Inc.’s earnings last quarter?
Alpha Teknova, Inc. released its earnings results on Mar 04, 2025. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.12 by $0.01.
Is Alpha Teknova, Inc. overvalued?
According to Wall Street analysts Alpha Teknova, Inc.’s price is currently Undervalued.
Does Alpha Teknova, Inc. pay dividends?
Alpha Teknova, Inc. does not currently pay dividends.
What is Alpha Teknova, Inc.’s EPS estimate?
Alpha Teknova, Inc.’s EPS estimate is -0.11.
How many shares outstanding does Alpha Teknova, Inc. have?
Alpha Teknova, Inc. has 53,436,806 shares outstanding.
What happened to Alpha Teknova, Inc.’s price movement after its last earnings report?
Alpha Teknova, Inc. reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.12. Following the earnings report the stock price went down -1.159%.
Which hedge fund is a major shareholder of Alpha Teknova, Inc.?
Currently, no hedge funds are holding shares in TKNO
---
Alpha Teknova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (50.38% Upside)
$10.00 (50.38% Upside)
Hedge Fund Trend
Decreased
By 531.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
281.76%
12-Months-Change
Fundamentals
Return on Equity
-31.02%
Trailing 12-Months
Asset Growth
-7.64%
Trailing 12-Months
Company Description
Alpha Teknova, Inc.
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
---
TKNO Company Deck
---
TKNO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant growth in clinical customers and key segments like custom biopharma while also noting improvements in operational efficiency and cash flow. However, challenges included flat overall revenue growth, a decline in gross margins, and market-specific hurdles that tempered the company's outlook.Read More>---
TKNO Stock 12 Month Forecast
Average Price Target
$10.00
▲(50.38% Upside)
Technical Analysis
Emergent Biosolutions
―
Lifecore Biomedical
―
Rockwell Med
―
SIGA Technologies
―
Aquestive Therapeutics
―
Best Analysts Covering TKNO
1 Year
1 Year Success Rate
1/3 ratings generated profit
1 Year Average Return
-4.73%
reiterated a buy rating 2 months ago
Copying Matt Larew's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -4.73% per trade.
---